RT Journal
A1 Legrand M, Mateo J, Aribaud A, et al
T1 THe use of dabigatran in elderly patients
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2011
FD July 25
VO 171
IS 14
SP 1285
OP 1286
DO 10.1001/archinternmed.2011.314
UL http://dx.doi.org/10.1001/archinternmed.2011.314
AB Recent approval by the US Food and Drug Administration (FDA) of dabigatran etexilate, an oral direct thrombin inhibitor, for the prevention of stroke in patients with atrial fibrillation will likely extend its administration in elderly patients. The risk of major overdosage of dabigatran etexilate in this population is, however, much increased owing to frequent renal function impairment, low body weight, drug interactions that cannot be detected with a routine coagulation test, and no antagonist available. We report herein 2 clinical cases, including 1 fatal case, illustrating our concern regarding the risk of bleeding events in elderly patients.